Skip to main content
An official website of the United States government
Government Funding Lapse
Because of a lapse in government funding, the information on this website may not be up to date, transactions submitted via the website may not be processed, and the agency may not be able to respond to inquiries until appropriations are enacted.

The NIH Clinical Center (the research hospital of NIH) is open. For more details about its operating status, please visit cc.nih.gov.

Updates regarding government operating status and resumption of normal operations can be found at opm.gov.

Lisinopril for the Prevention of Urinary Side Effects Following Radiation Therapy in Patients with Prostate Adenocarcinoma

Trial Status: active

This phase I trial studies the side effects and best dose of lisinopril for the prevention of urinary side effects following radiation therapy for prostate adenocarcinoma. Radiation therapy is often used for the treatment of prostate adenocarcinoma. Although it is highly effective for controlling prostate cancer, radiation therapy can injure the bladder and urethra, causing acute and late side effects that may last for many years, and sometimes never completely go away. Lisinopril is a type of angiotensin-converting enzyme inhibitor used to treat high blood pressure and certain heart conditions. It is also being studied in the prevention and treatment of side effects caused by some anticancer drugs. It blocks certain enzymes that cause blood vessels to constrict (narrow). This may improve blood flow to the urinary system, which may help prevent urinary side effects following radiation therapy for prostate adenocarcinoma.